晨光生物(300138) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥1,716,472,687.32, a decrease of 0.92% compared to ¥1,732,327,232.51 in the same period last year[4] - Net profit attributable to shareholders increased by 183.69% to ¥109,480,325.98 from ¥38,591,936.61 year-on-year[4] - Basic earnings per share increased by 212.55% to ¥0.2266 from ¥0.0725 in the same period last year[4] - Total operating revenue for the current period is ¥1,716,472,687.32, a slight decrease from ¥1,732,327,232.51 in the previous period, representing a decline of approximately 0.3%[33] - Net profit for the current period is ¥111,187,387.94, significantly up from ¥32,993,385.92 in the previous period, indicating an increase of approximately 236.5%[34] - Total comprehensive income for the period attributable to the parent company was ¥108,673,116.26, compared to ¥39,158,944.65 in the previous period, indicating a significant increase[35] - Basic and diluted earnings per share for the period were both ¥0.2266, up from ¥0.0725 in the previous period, reflecting strong earnings growth[35] Cash Flow and Investments - The net cash flow from operating activities rose by 168.67% to ¥530,444,407.97 compared to ¥197,431,523.85 in the previous year[4] - Cash inflow from investment activities totaled ¥1,098,489,002.42, compared to ¥663,619,546.35 in the previous period, showing improved investment returns[38] - Net cash flow from financing activities was ¥1,169,991,139.63, up from ¥466,160,475.40 in the prior period, indicating increased financing activities[38] - The company reported a net cash increase of ¥221,489,215.92 for the period, a decrease from ¥1,133,320,946.58 in the previous period[38] - The ending balance of cash and cash equivalents was ¥736,291,455.94, down from ¥2,218,585,909.30 in the previous period, reflecting cash management strategies[38] - The company received cash from the recovery of investments amounting to ¥1,084,403,155.60, compared to ¥648,538,819.00 in the previous period, indicating effective investment recovery[38] - Cash paid for purchasing fixed assets and other long-term assets was ¥25,054,833.31, down from ¥34,050,563.38 in the previous period, showing cost control in capital expenditures[38] Assets and Liabilities - Total assets at the end of the reporting period reached ¥10,297,428,971.06, reflecting a growth of 14.13% from ¥9,022,520,660.60 at the end of the previous year[4] - The company's total liabilities increased to ¥7,032,359,613.94 from ¥5,867,831,481.69, representing a rise of approximately 19.8%[32] - The company's total equity rose to ¥3,265,069,357.12 from ¥3,154,689,178.91, indicating an increase of approximately 3.5%[32] Research and Development - Research and development expenses increased by 80.30% year-on-year, indicating a significant rise in investment in innovation[15] - Research and development expenses increased to ¥41,738,594.25 from ¥23,149,384.73, showing a growth of about 80.4%[34] Business Segments and Operations - Revenue from plant extract business, including natural pigments/spices/nutrition and sweeteners, reached 867 million yuan, a year-on-year increase of 13.78%, with a gross profit margin improvement of 2.15%[26] - Sales of chili red pigment increased by approximately 7% due to a rise in sales volume, while chili extract sales volume doubled, leading to a revenue increase of about 24%[27] - The sweet stevia glycoside market saw a sales growth of approximately 40%, with revenue surpassing 80 million yuan, a year-on-year increase of about 55%[28] - The company reported a significant improvement in cottonseed business, achieving profitability after implementing strict operational management to mitigate price volatility risks[28] - The company expanded its product offerings in health foods, traditional Chinese medicine, and raw materials, leveraging its advantages in raw materials and technology research and development[28] - The gross profit from the plant extract business was approximately 175 million yuan, reflecting a year-on-year growth of about 27.31%[26] - The company maintained a stable area for raw material bases, actively promoting trial planting of marigold in Myanmar to enhance raw material advantages for lutein[27] - The company reported a significant increase in sales volume for food-grade lutein, with a year-on-year growth of 50%[27] Shareholder Information - The total number of ordinary shareholders increased from 17,585 at the end of January 2025 to 24,340 by April 20, 2025[25] Financing Activities - The company’s short-term borrowings increased by 59.68%, indicating a rise in financing activities[11] - Short-term borrowings surged to ¥3,678,890,922.00 from ¥2,303,903,150.25, reflecting an increase of about 59.8%[32]